Alnylam’s CEO acknowledges the company must improve as uncertainty continues to cloud the outlook for its transthyretin franchise and raises questions about the future of this key business area.

Alnylam’s CEO acknowledges the company must improve as uncertainty continues to cloud the outlook for its transthyretin franchise and raises questions about the future of this key business area.